Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2020

View Archived Issues

IND clearance paves way for phase II study of BXCL-501 for agitation associated with delirium

Phase II study of SHR-0302 in atopic dermatitis meets primary and secondary endpoints

Crinetics presents phase II data from ACROBAT Edge and ACROBAT Evolve studies of paltusotine

ADXS-503 shows pronounced and sustained tumor control in ongoing phase I/II study in NSCLC

CohBar presents promising preclinical data for its antifibrotic CB5138 analogue peptides

Olema and Novartis to evaluate OP-1250 in combination therapies

NOI initiates phase IIb/IIIa trial of first oral systemic NO-based therapeutic for COVID-19

Shanghai Ringene Biopharma describes new STAT3 inhibitors

ENA 2020: Progress in cancer research can come one mouse at a time, study suggests

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent anti-claudin 18.2 antibodies

First cohort successfully completed in phase I study of HFB-30132A

New SGLT-1 inhibitors identified at Medshine Discovery

Shanghai Synergy Pharmaceutical Sciences, Zhejiang Huahai Pharmaceutical present BRD4 inhibitors

Prenatal treatment normalizes brain development in Down syndrome model

Dual HDAC6/VEGFR-2 inhibitors presented by Beijing Guohong Biomedical Technology

Positive interim phase II data presented for olutasidenib in AML

BioInvent receives CTA approval for first-in-human study of BI-1808 in Denmark

Ascentage cleared to begin phase Ib/II study of APG-115 for liposarcoma in China

ViralClear halts phase II study of merimepodib in hospitalized patients with COVID-19

Preclinical and clinical data presented for taminadenant + spartalizumab in cancer

GABPB1-AS1 is correlated with poor prognosis in HPV16-positive cervical cancer

APJ-specific PET radiotracer predictive of post-ischemic angiogenesis

Novel SARS-CoV-2 subunit vaccine in preclinical development

Interim data reported from phase I/II study of GTX-102 for Angelman syndrome

FDA approves IND for phase II study of VSJ-110 for allergic conjunctivitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Pharma industry faces long haul to get return on investment from AI
BioWorld Science
Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on...